PERSPECTIVE THERAPEUTICS INC (CATX)
US46489V3024 - Common Stock
PERSPECTIVE THERAPEUTICS INC
NYSEARCA:CATX (10/14/2024, 8:18:10 PM)
After market: 12.29 0 (0%)12.29
-0.37 (-2.92%)
Company Profile
Perspective Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 116 full-time employees. The company went IPO on 2002-05-31. Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is developing advanced treatment applications for cancers throughout the body. The firm has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The company is also developing imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. The firm's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase I/IIa imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several academic institutions. The company has also developed a 212Pb generator to secure key isotopes for clinical trial and commercial operations.
Company Info
PERSPECTIVE THERAPEUTICS INC
2401 Elliott Avenue, Suite 320
Seattle WASHINGTON
P: 12066760900
Employees: 118
Website: https://isoray.com/
CATX News
4 days ago - ChartmillThere are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
4 days ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research[212Pb]VMT01 was observed to be safe, and no dose-limiting toxicities were observed at the two doses tested (3.0 and 5.0 mCi)Prolonged progression-free...
5 days ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma ResearchSEATTLE, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
8 days ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma DaySEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
15 days ago - Perspective Therapeutics, Inc.Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear MedicineSEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
a month ago - Perspective Therapeutics, Inc.Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive MelanomaSEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical...
CATX Twits
Here you can normally see the latest stock twits on CATX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
